Twist Bioscience Corporation (TWST) Research

Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.

Market snapshot

Symbol
TWST
Price
$87.56
Day change
+5.66%
Market cap
$5.5B
P/E ratio
-66.33x
52-week range
23.3-88.46
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Next earnings
in 1 month
Analyst price target
$75.00

Recent news

  • Ozempic Linked To Lower Risk Of Violence In New Study

    The researchers said the findings are not causal and urged more research into whether GLP-1s reduce the risk of violence. Daniel Semenza, lead author of the study and director of research at the New Jersey Gun Violence Research Center at the Rutgers School of Public Health, said it is important to continue studying the impact of GLP-1 medications on users' behavior and public safety as the medications become more widespread.

  • These Analysts Boost Their Forecasts On Twist Bioscience After Q2 Results

    Twist Bioscience Corporation (NASDAQ:TWST) on Monday reported a loss for its fiscal 2026 second quarter.

  • AI-Driven Demand Boosts Twist Bioscience Sales, But Loss Widens

    Twist Bioscience Corporation (NASDAQ:TWST) shares are down on Monday as the company reported its fiscal 2026 second-quarter financial results.

Peer companies

  • BGM Group Ltd. (BGM)
  • Clover Health Investments, Corp. (CLOV)
  • Edgewise Therapeutics, Inc. (EWTX)
  • Structure Therapeutics Inc. (GPCR)
  • Guardian Pharmacy Services, Inc. (GRDN)
  • Mesoblast Limited (MESO)
  • PROCEPT BioRobotics Corporation (PRCT)
  • QuidelOrtho Corporation (QDEL)

Recent insider activity

  • Green Paula — M-Exempt (26137 shares) on 2026-06-15
  • Green Paula — S-Sale (24109 shares) on 2026-06-15
  • Green Paula — S-Sale (2028 shares) on 2026-06-15
  • Green Paula — M-Exempt (26137 shares) on 2026-06-15
  • Cho Dennis — S-Sale (402 shares) on 2026-06-08

Open Twist Bioscience Corporation (TWST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.